BusinessCellular Biomedicine Group Announces Positive 48-Week Clinical Data of AlloJoin™ Human Adipose-Derived Mesenchymal Progenitor Cell (haMPC) Knee Osteoarthritis (KOA) China Phase I TrialBy Nasdaq OMXMar 16, 2018, 11:00 AM UTC
BusinessCellular Biomedicine Group Announces Upcoming Presentation to Release 48-Week Data from Phase I Clinical Trial for AlloJoin™ Off-the-Shelf Allogeneic Stem Cell Therapy for Knee OsteoarthritisBy Nasdaq OMXMar 14, 2018, 11:30 AM UTC
BusinessCellular Biomedicine Group Announces Results of 2017 Annual Meeting of StockholdersBy Nasdaq OMXMay 1, 2017, 8:01 PM UTC
BusinessCellular Biomedicine Group Awarded $2.29 Million Grant from the California Institute for Regenerative Medicine (CIRM) to Fund AlloJoin™ Allogeneic Stem Cell Therapy for Knee Osteoarthritis (KOA) in the U.S.By Nasdaq OMXFeb 27, 2017, 1:01 PM UTC
BusinessCellular Biomedicine Group Announces Three-Month Interim Safety Data from Phase I Clinical Trial for AlloJoin™ Off-the-Shelf Allogeneic Stem Cell Therapy for Knee OsteoarthritisBy Nasdaq OMXDec 9, 2016, 1:00 PM UTC
BusinessCellular Biomedicine Group Launches Phase I Clinical Trial for AlloJoin™ Off-the-Shelf Allogeneic Stem Cell Therapy for Knee OsteoarthritisBy Nasdaq OMXJan 6, 2016, 2:04 PM UTC
